January 18, 2017 Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
January 5, 2017 Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
December 13, 2016 Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
November 18, 2016 Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
November 15, 2016 Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
November 14, 2016 Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants
November 1, 2016 Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and Financial Results
